Phase IV study to evaluate the efficacy of aflibercept in subjects with neovascular age-related macular degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of anti VEGF-A therapy.
- Registry ID
- EUCTR2013-000848-26
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- Barcelona Macula Foundation
- Start date
- 2013-07-04
- Last update
- 2026-08-16
Conditions
- Wet age-related macular degeneration
Summary
To study the efficacy of aflibercept treatment of wAMD patients without optimal response to anti VEGF-A therapy, in terms of the percentage of patients with no fluid on OCT after loading dose (intra or subretinal) of aflibercept (3 initial monthly doses).
Locations
View on source registry